Valuation: Alvotech

Market Cap 1.18B 1.04B 956M 883M 1.68B 113B 1.7B 11.42B 4.49B 55.67B 4.45B 4.35B 191B P/E 2026 *
9.01x
P/E 2027 * 7.69x
Enterprise Value 2.23B 1.95B 1.8B 1.66B 3.16B 213B 3.21B 21.53B 8.45B 105B 8.38B 8.2B 361B EV / Sales 2026 *
3.38x
EV / Sales 2027 * 2.83x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.05%
1 week-8.03%
Current month-10.03%
1 month-20.19%
3 months-7.78%
6 months-28.45%
Current year-35.28%
1 week 3.24
Extreme 3.245
3.72
1 month 3.24
Extreme 3.245
4.45
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Sell

Founder

318,000 0.0963%
01/04Free

Chief Executive Officer

117,271 0.0355%
01/04Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-8.03%-62.01%-61.97% 1.18B
+0.58%+2.06%+2.92%+10.86% 50.44B
-1.93%-0.93%+388.88%+591.73% 40.63B
-0.87%+0.64%+25.22%-5.54% 34.88B
-1.44%-3.33%+18.06%+55.38% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-2.01%+0.82% - - 17.11B
+0.55%-4.83%+63.84%+122.42% 15.29B
-8.83%-28.98%+39.39%+41.40% 10.62B
+0.23%-0.58%+13.76%+21.11% 13.74B
Average -1.34%-2.71%+54.95%+90.06% 24.39B
Weighted average by Cap. -0.84%-0.07%+84.07%+131.05%

Financials

2026 *2027 *
Net sales 661M 578M 533M 492M 934M 63.02B 950M 6.37B 2.5B 31.05B 2.48B 2.43B 107B 800M 700M 645M 596M 1.13B 76.28B 1.15B 7.71B 3.03B 37.58B 3B 2.94B 129B
Net income 165M 144M 133M 123M 233M 15.7B 237M 1.59B 623M 7.73B 618M 605M 26.59B 134M 118M 108M 100M 190M 12.82B 193M 1.3B 509M 6.31B 505M 494M 21.7B
Net Debt 1.05B 917M 846M 781M 1.48B 99.97B 1.51B 10.1B 3.97B 49.25B 3.94B 3.85B 169B 1.08B 945M 872M 805M 1.53B 103B 1.55B 10.42B 4.09B 50.78B 4.06B 3.97B 175B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
09/07/26 USD 3.320 -2.35% 629,021
08/07/26 USD 3.400 -2.58% 385,125
07/07/26 USD 3.490 +0.87% 638,832
06/07/26 USD 3.460 -4.16% 622,363
02/07/26 USD 3.610 +0.84% 479,403
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.320USD
Average target price
14.60USD
Spread / Average Target
+339.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock